Background: Pneumococcal pneumonia is a major cause of morbidity and mortality worldwide. Efficacy of pneumococcal conjugate vaccines (PCV) in reducing childhood pneumonia has been estimated in four double-blind, randomized, controlled trials. An investigational 11-valent pneumococcal conjugate vaccine (11PCV) had an efficacy of 22.9% against radiologically defined pneumonia during first 2 years of life in Filipino infants. We report here the immunogenicity of the vaccine in a nested study of 1111 infants randomized 1:1 to receive 11PCV or placebo scheduled to be given according to the National EPI Program at 6, 10, and 14 weeks of age.
Methods: IgG antibody concentrations to pneumococcal capsular polysaccharides were measured by a standardized enzyme immuno-assay in serum samples drawn post-3rd dose for peak antibody response and at the time of measles vaccination at 9 months of age for persistence of the antibodies.
Results: The geometric mean concentrations (GMCs) of antibodies were significantly higher in 11PCV than in placebo recipients against vaccine serotypes at both sampling points. One month post-3rd dose, 93-100% of 11PCV recipients had > or =0.35microg/ml for 9 serotypes, 76% for 6B, and 87% for 23F. The same proportions varied between 24% and 97% at 9.5 months of age due to antibody decrease. GMC to vaccine-related serotype 19A, but not to 6A, was higher in 11PCV than in placebo recipients. 7-12% of the 11PCV recipients had spontaneous antibody increases to serotypes 6B, 23F, and 14 between the two sampling points. These serotypes were common in nasopharyngeal samples of the infants.
Conclusion: The 11PCV demonstrated good immunogenicity after three doses and persistence of antibodies at least up to 9.5 months of age, comparable to other PCVs that have been evaluated for efficacy against radiologically defined pneumonia in other populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2009.02.059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward.
Clin Microbiol Rev
January 2025
Department of Medicine, Division of Pulmonary/Allergy/Critical Care, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
SUMMARY (the "pneumococcus") is a significant human pathogen. The key determinant of pneumococcal fitness and virulence is its ability to produce a protective polysaccharide (PS) capsule, and anti-capsule antibodies mediate serotype-specific opsonophagocytic killing of bacteria. Notably, immunization with pneumococcal conjugate vaccines (PCVs) has effectively reduced the burden of disease caused by serotypes included in vaccines but has also spurred a relative upsurge in the prevalence of non-vaccine serotypes.
View Article and Find Full Text PDFSerotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study.
Expert Rev Vaccines
December 2025
South Africa Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa.
Background: Due to high costs of pneumococcal conjugate vaccines (PCV), transitioning from a two (2 + 1) to a single dose (1 + 1) primary series with a booster should be considered. This study evaluated the immune response at 18 months of age following a 1 + 1 compared to a 2 + 1 schedule of 10-valent (PCV10) and 13-valent (PCV13) vaccines.
Research Design And Methods: A single-center, open-label, randomized trial conducted in Soweto, South Africa, evaluated the immunogenicity of differing dosing schedule for PCV10 and PCV13.
Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.
J Infect
January 2025
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.
Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.
Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally.
Immunisation schedule of the Pediatric Spanish Association: 2024 recommendations.
An Pediatr (Engl Ed)
January 2025
Pediatrician, Barcelona, Spain.
The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.
View Article and Find Full Text PDFEmerging of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-vallent pneumococcal conjugate vaccine era in Moshi district, Tanzania. A short communication.
Vaccine
January 2025
Section Pediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
In this study, we describe S. pneumoniae serotype distribution before and after PCV13 rollout in Tanzania. We serotyped S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!